Production of Secretory IgA with Increased Stability
Established IgA producing cell lines can be transfected with the SC component to produce sIgA with identical specificity. Can create new sIgA monoclonal antibodies produced in large quantities from a single cell line using standard antibody production techniques. sIgA has increased stability compared to currently available IgA monoclonal antibodies.
Production of stable, sIgA monoclonal antibodies.
UCLA researchers have developed a process to produce stable sIgA from a single mammalian cell in quantities practical for therapeutic uses. Vectors and cell lines for producing non-secretory IgA are readily available. In order to easily produce sIgA from these same cell types, a vector encoding the secretory signal is transfected into the IgA producing cell lines and stable transductants are cloned. In vitro and in vivo stability of the sIgA was measured and sIgA was found to have significantly greater stability than monoclonal IgA lacking SC. This invention provides a solution for the need for large quantities of sIgA monoclonal therapeutic antibodies.
Patent Number: US6300104B1
Application Number: US199895385A
Inventor: Morrison, Sherie L. | Chintalacharuvu, Kote R.
Priority Date: 19 Jun 1997
Priority Number: US6300104B1
Application Date: 10 Jun 1998
Publication Date: 9 Oct 2001
IPC Current: A61K0039395 | A61P003704 | C07K001600 | C12P002104 | A61K003800
US Class: 43507021 | 4241331 | 4241411 | 4241471 | 4350701 | 4350702 | 4353201 | 435326 | 435328 | 435339 | 5303871 | 530808
Assignee Applicant: The Regents of the University of California
Title: Secretory immunoglobulin produced by single cells and methods for making and using same
Usefulness: Secretory immunoglobulin produced by single cells and methods for making and using same
Summary: USE The method is useful to produce commercial quantities of sIg (especially sIgA) to treat or prevent infections. In particular, sIgA produced by the method can be combined with a carrier in pharmaceutical compositions (claimed), which can be administered to prevent/treat infections (claimed) especially in mammals (particularly humans), birds or fish (claimed). Such compositions can be used to prevent or treat bacterial, viral, mycoplasmal, mycobacterial, yeast or parasitic infections, especially systemic infections or infections at a mucosal surface (claimed). They are especially useful to prevent or treat human infection with human immunodeficiency virus (HIV), respiratory syncytial virus, flu virus or cold virus (claimed). SIgA is usually found in external secretions such as colostrum, saliva, tears etc. and is often the first line of defence against infectious agents in the body.
Novelty: Producing secretory immunoglobulin in single cells useful to produce commercial quantities of secretory immunoglobulin to prevent or treat infections
診斷/治療
人類免疫缺陷病毒
6300104
Background The immunoglobulin secretory IgA (sIgA) is found in mucosal surfaces is often the first line of defense against infectious agents. Normally, sIgA is the product of two different cell types with heavy, light, and J chains produced by plasma cells, whereas the secretory component (SC) is added by cellular enzymes during transit of the dimeric IgA through the epithelial cell layer.The SC component of sIgA provides for stability at the mucosal surfaces. Currently available monoclonal IgA which lacks SC, while protective, is rapidly degraded. Attempts have been made to create sIgA in vitro by either co-culturing IgA producing cells with polarized epithelial cells or by adding SC exogenously to purified IgA, however, both methods provide very low yields of sIgA. Additional Technologies by these Inventors Tech ID/UC Case 20097/1997-545-0 Related Cases 1997-545-0
美國
